Jade Biosciences (JBIO) said late Wednesday it plans to offer shares, or pre-funded warrants to purchase shares, in an underwritten public offering.
Jade said it intends to grant its underwriters a 30-day option to buy up to an additional 15% of the securities offered.
Net proceeds will be used among others for clinical trials, pre-clinical studies, and working capital, the clinical-stage firm said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.